Skip to content
HowShorted

Allogene Therapeutics, Inc. short interest in 2021

In 2021, Allogene Therapeutics, Inc.'s disclosed short interest ran from 9.78% of shares outstanding on 15 Jan 2021 to 5.32% on 31 Dec 2021, a change of -4.46 percentage points. The year's high was 9.78% on 15 Jan 2021 and its low 3.32% on 15 Oct 2021, averaging 5.93% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.76 days on 12 Feb 2021. Full history: Allogene Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Allogene Therapeutics, Inc. in 2021

2021 in figures

Start of year
9.78% (15 Jan 2021)
End of year
5.32% (31 Dec 2021)
Change
-4.46 pp
High
9.78% (15 Jan 2021)
Low
3.32% (15 Oct 2021)
Average
5.93%
Highest days to cover
19.76 (12 Feb 2021)
SEC filings marked
8

Every report in 2021

Allogene Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20219.78%18.12
29 Jan 20218.22%13.63
12 Feb 20217.90%19.76
26 Feb 20218.23%19.5410-K filed, results (8-K)
15 Mar 20217.33%9.50
31 Mar 20216.15%11.18
15 Apr 20215.92%13.82
30 Apr 20215.17%11.94
14 May 20215.82%8.7910-Q filed, results (8-K)
28 May 20215.62%3.39
15 Jun 20215.78%7.00
30 Jun 20216.69%5.28
15 Jul 20216.70%10.79
30 Jul 20216.55%18.62
13 Aug 20215.89%12.3010-Q filed, results (8-K)
31 Aug 20215.87%10.29
15 Sep 20215.52%13.65
30 Sep 20215.61%10.72
15 Oct 20213.32%1.00
29 Oct 20213.34%3.55
15 Nov 20213.98%3.9210-Q filed, results (8-K)
30 Nov 20213.77%5.99
15 Dec 20213.95%3.49
31 Dec 20215.32%5.80

See also: Allogene Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.